Selective cyclooxygenase-2 (COX-2) inhibitors and potential risk of cardiovascular events

Biochemical Pharmacology
D Mukherjee

Abstract

Selective cyclooxygenase-2 (COX-2) inhibitors were developed as a response to the gastrointestinal toxicity of conventional nonsteroidal anti-inflammatory agents (NSAIDs). However, COX-2 inhibitors decrease vascular prostacyclin (PGI(2)) production and may disrupt the homeostatic mechanisms that limit the effects of platelet activation. Basic and clinical data raise concerns about a potential prothrombotic effect of this class of drugs. The widespread popularity of these agents mandates their prospective evaluation in patients with cardiovascular diseases or who are at risk for cardiovascular events.

References

Nov 27, 1998·Inflammation Research : Official Journal of the European Histamine Research Society ... [et Al.]·J R Vane, R M Botting
Jan 6, 1999·Proceedings of the National Academy of Sciences of the United States of America·B F McAdamG A FitzGerald
Jan 20, 2000·The New England Journal of Medicine·UNKNOWN Heart Outcomes Prevention Evaluation Study InvestigatorsG Dagenais
Aug 30, 2000·Proceedings of the National Academy of Sciences of the United States of America·K ShinmuraR Bolli
Nov 23, 2000·The New England Journal of Medicine·C BombardierUNKNOWN VIGOR Study Group
Feb 15, 2001·Cardiology in Review·W Koenig
Aug 31, 2001·JAMA : the Journal of the American Medical Association·D MukherjeeE J Topol

❮ Previous
Next ❯

Citations

Sep 1, 2005·Digestive Diseases and Sciences·Yasuhiro AraiTohru Mizushima
Sep 28, 2005·Digestive Diseases and Sciences·Wataru TomisatoTohru Mizushima
Mar 24, 2004·Biochemical Pharmacology·Wataru TomisatoTohru Mizushima
Oct 27, 2004·Critical Reviews in Oncology/hematology·J B TuynmanD J Richel
Nov 3, 2005·Nature Clinical Practice. Cardiovascular Medicine·Gary Spektor, Valentin Fuster
May 12, 2004·Nature Reviews. Drug Discovery·Derek W GilroyAdriano G Rossi
Oct 28, 2009·Journal of Medicinal Food·Sarah L MorganAngela C Kendrach
Feb 18, 2012·Pharmacogenetics and Genomics·Li GongTeri E Klein
Mar 2, 2010·Biological & Pharmaceutical Bulletin·Naoki YamakawaTohru Mizushima
Mar 27, 2003·Drugs·Gysèle S BleuminkBruno H Ch Stricker
Sep 21, 2005·Proceedings of the National Academy of Sciences of the United States of America·Zachary R HealyKonstantinos Konstantopoulos
Oct 2, 2004·Dermatologic Surgery : Official Publication for American Society for Dermatologic Surgery [et Al.]·Maryam AsgariMary-Margaret Chren
Feb 15, 2011·Journal of Enzyme Inhibition and Medicinal Chemistry·Mymoona AkhterA Kumar
Aug 9, 2003·The Journal of Pharmacy and Pharmacology·Naveen AhujaBhupinder Singh
Apr 11, 2008·Congestive Heart Failure·Debabrata Mukherjee
Dec 14, 2006·Prostaglandins & Other Lipid Mediators·Jamie J O'BrienRichard P Phipps
Nov 16, 2010·Journal of Ethnopharmacology·Weifeng LiLangchong He
Oct 2, 2012·Biochemical Pharmacology·Shintaro SuemasuTohru Mizushima
Dec 25, 2012·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Paul J LimburgUNKNOWN Cancer Prevention Network
Sep 16, 2016·Hypertension Research : Official Journal of the Japanese Society of Hypertension·Ai FujitaToshiyuki Sasaguri
Mar 22, 2014·Bioorganic & Medicinal Chemistry·Naoki YamakawaTohru Mizushima
Jul 10, 2004·Menopause : the Journal of the North American Menopause Society·Pilar J OviedoAntonio Cano
Mar 7, 2017·Chinese Journal of Natural Medicines·Zhipin Liang, Yaguang Xi
Jun 21, 2005·Journal of Cardiovascular Pharmacology and Therapeutics·Karsten SchrörJawahar L Mehta
Oct 27, 2011·Pharmaceuticals·Priscila Longhin BosquesiMan Chin Chung
May 25, 2010·Pharmaceuticals·Tohru Mizushima
May 25, 2010·Pharmaceuticals·Gary A PiazzaRobert C Reynolds
Nov 7, 2017·Medicinal Chemistry Research : an International Journal for Rapid Communications on Design and Mechanisms of Action of Biologically Active Agents·Bini MathewRobert C Reynolds
Mar 26, 2004·Anesthesia and Analgesia·Alex M BlaicherKlaus Hoerauf

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.